Table 1. Deconstruction of the 5-chloro-2-(2-(dimethylamino)ethoxy)aniline substituent.
| ID |
|
EC50(Nurr1) (max. activation) a |
|---|---|---|
| 4 |
|
3±1 μM (1.3±0.1-fold) |
| 5 |
|
inactive (10 μM) |
| 6 |
|
inactive (10 μM) |
| 7 |
|
inactive (10 μM) |
| 8 |
|
0.06±0.03 μM (1.5±0.1-fold) |
| 9 |
|
0.7±0.1 μM (1.4±0.1-fold) |
| 10 |
|
0.6±0.2 μM (1.5±0.1-fold) |
| 11 |
|
1.5±0.1 μM (1.6±0.1-fold) |
| 12 |
|
0.08±0.02 μM (1.4±0.1-fold) |
| 13 |
|
inactive (10 μM) |
| 14 |
|
0.5±0.2 μM (1.5±0.1-fold) |
| 15 |
|
0.33±0.09 μM (1.6±0.1-fold) |
| 16 |
|
1.0±0.2 μM (1.4±0.1-fold) |
| 17 |
|
1.0±0.2 μM (1.3±0.1-fold) |
| 18 |
|
1.7±0.5 μM (1.3±0.1-fold) |
Nurr1 modulation was determined in a Gal4-Nurr1 hybrid reporter gene assay. Max. activation refers to the maximum effect vs. 0.1% DMSO control. Data are the mean±SD; n≥3.